Grifols and Alzheimer's

Grifols and Alzheimer's

Since 2004, we have led a broad range of research initiatives on Alzheimer's as part of our commitment to making a positive difference in the lives of people who suffer from this devastating disease.

Our Alzheimer's research began when a scientific article highlighted that albumin, the most common protein in plasma, might have the ability to capture beta-amyloid, one of the proteins that builds up in the brains of patients with Alzheimer's.

Grifols conducted a small clinical study aimed at proving that concept. This initial research paved the way for a second, larger study involving 42 patients in the U.S. and Spain. In 2013, the promising results of these early investigations led to a full-scale clinical trial that we called AMBAR: Alzheimer Management by Albumin Replacement.

The AMBAR trial was designed to evaluate whether the progression of Alzheimer's could be stabilized through therapeutic plasma exchange, a process that entails periodically extracting plasma and infusing the plasma protein albumin (Albutein®) with or without intravenous immunoglobulin (Flebogamma DIF®).

The study is our most ambitious clinical trial to date, but it is not our only line of investigation. Our commitment to alleviating the Alzheimer's epidemic is ongoing. Over the past 15 years we have invested more than €150 million in Alzheimer's research, including innovative projects focused on early diagnosis and investigating a prevention vaccine.

AMBAR's results are encouraging and show that plasma-protein-replacement therapy slows down the progression of the disease in patients with mild-to-moderate Alzheimer's.

Grifols is committed to continuing investigating this debilitating condition that has a tremendous impact on the quality of life of patients, their families and caregivers.